Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

NCT01984788 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

NCT00456508 ·Status: COMPLETED ·Phase: PHASE3

Expanded Access for Hereditary Angioedema (HAE)

NCT03177005 ·Status: APPROVED_FOR_MARKETING

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739 ·Status: COMPLETED ·Phase: PHASE2

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

NCT05489640 ·Status: COMPLETED

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

NCT04130191 ·Status: COMPLETED

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911 ·Status: COMPLETED ·Phase: PHASE3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881 ·Status: RECRUITING ·Phase: PHASE3

Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations

NCT00004694 ·Status: COMPLETED ·Phase: NA

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007 ·Status: NO_LONGER_AVAILABLE

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080 ·Status: COMPLETED ·Phase: PHASE3

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

NCT03845400 ·Status: COMPLETED

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

NCT05469789 ·Status: ACTIVE_NOT_RECRUITING

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

NCT05147181 ·Status: COMPLETED

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

NCT01541423 ·Status: COMPLETED

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00225147 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

NCT03240133 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353 ·Status: COMPLETED ·Phase: PHASE3

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211 ·Status: COMPLETED ·Phase: PHASE2

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779 ·Status: COMPLETED ·Phase: PHASE3

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015 ·Status: COMPLETED ·Phase: PHASE3